News Amarantus BioScience Holdings, Inc.

Equities

AMBS

US02300U2050

Market Closed - OTC Markets Other stock markets 12:12:15 2024-05-08 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	-80.00%

2022	Sector Update: Financial Stocks Still Adding to Wednesday Declines	MT
2020	Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Financial Stocks Still Adding to Wednesday Declines	22-03-30	MT
Amarantus BioScience : Notification of Late Filing	21-11-18	PU
Amarantus BioScience : Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus	20-07-28	AQ
Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.	20-07-27	CI
Emerald Organic Products : Restructures Joint Venture Agreement With Todos Medical by Entering Joint Collaboration Agreement	20-05-08	AQ
Amarantus BioScience : Todos Medical and 3DMed Enter Into Coronavirus (COVID-19) and Influenza A/B Testing Kit Distribution Agreement in US and Israel	20-03-17	AQ
Amarantus BioScience : Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International	20-02-06	AQ
Amarantus Releases Letter to Shareholders	20-02-04	GL
Amarantus Acquires Majority Interest in CBD Wellness Company Hempori	20-01-30	GL
Amarantus BioScience Holdings, Inc. acquired majority interest in Hempori, Inc. for $0.38 million.	20-01-29	CI
Emerald Organic Products : Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products	20-01-02	AQ
Amarantus Completes Sublicense of ESS, MANF and Phenoguard to Emerald Organic Products	20-01-02	CI
Amarantus to Present at 12th Annual LD Micro Main Event	19-12-09	GL
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease	19-12-04	GL
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics	19-11-21	GL
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary Manf Therapeutics	19-11-21	CI
Amarantus Provides Recapitalization Update to Shareholders	19-11-18	GL
Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products	19-10-24	GL
Amarantus Bioscience Holdings, Inc. Enters into Agreement to License Diverse Therapeutics Portfolio to CBD-Focused Emerald Organic Products with Emerald Organic Growth, Inc	19-10-24	CI
Coeptis Pharmaceuticals, Inc. terminated the acquisition of Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..	19-10-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Amarantus BioScience Holdings, Inc.

Equities

AMBS

US02300U2050

Summary

Filters